Keurig Dr Pepper Inc. Common Stock vs Novo Nordisk A/S — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $31.76 (market cap $42.54B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.9× Keurig Dr Pepper Inc. Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 1 Days and Novo Nordisk A/S for 116 Days on average.
| KDP | NVO | |
|---|---|---|
Market Cap | $42.54B | $165.31B |
Volume | 14,530,234 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $63.98 |
52-Week Low | $25.31 | $35.29 |
Typical Hold Time | 1 Days | 116 Days |
Enterprise Value | $71.00B | $179.56B |
Dividend Yield | 2.94% | 4.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →